Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Operating Income: 2017-2025

Historic Operating Income for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to $9.6 million.

  • Puma Biotechnology's Operating Income fell 56.64% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.6 million, marking a year-over-year increase of 3.58%. This contributed to the annual value of $31.0 million for FY2024, which is 5.13% down from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's Operating Income is $9.6 million, which was up 44.26% from $6.6 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Operating Income registered a high of $22.1 million during Q3 2024, and its lowest value of -$16.6 million during Q2 2021.
  • Moreover, its 3-year median value for Operating Income was $6.6 million (2025), whereas its average is $7.6 million.
  • Its Operating Income has fluctuated over the past 5 years, first tumbled by 333.31% in 2021, then surged by 2,091.25% in 2022.
  • Quarterly analysis of 5 years shows Puma Biotechnology's Operating Income stood at -$503,000 in 2021, then spiked by 2,091.25% to $10.0 million in 2022, then spiked by 47.74% to $14.8 million in 2023, then dropped by 9.68% to $13.4 million in 2024, then plummeted by 56.64% to $9.6 million in 2025.
  • Its last three reported values are $9.6 million in Q3 2025, $6.6 million for Q2 2025, and $4.0 million during Q1 2025.